---
title: "General Atlantic Discloses Investment at Seaport Therapeutics with 11.5% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286010382.md"
description: "General Atlantic, L.P. has disclosed an 11.5% stake in Seaport Therapeutics, Inc. following its IPO. The firm filed a Schedule 13D on May 11, 2026, indicating a shift towards more active engagement with the company. General Atlantic plans to collaborate with shareholders and may suggest operational changes or board composition. A 180-day lock-up period restricts sales, but the firm may adjust its position post-lock-up. General Atlantic is known for investing in long-term growth in healthcare, technology, and life sciences sectors."
datetime: "2026-05-11T23:56:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286010382.md)
  - [en](https://longbridge.com/en/news/286010382.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286010382.md)
---

# General Atlantic Discloses Investment at Seaport Therapeutics with 11.5% Stake

General Atlantic, L.P. disclosed an 11.5% stake in Seaport Therapeutics, Inc. common stock. The group filed a Schedule 13D on May 11, 2026, after Seaport’s May 4 IPO converted its preferred shares and the fund bought additional shares at $18.00 in the offering. The shift from a prior 13G eligibility to a 13D signals room for more active engagement.

**Investor Intent**

General Atlantic says it holds the shares for investment and plans to engage with other shareholders, company leaders, and directors. The firm may "make suggestions concerning the Company's operations" and board composition, and it could buy more shares or sell shares over time based on how the business performs.

A lock-up limits sales and hedging for 180 days after May 1, 2026, with transfers only to affiliates that honor the same terms. Beyond the lock-up, General Atlantic "may, from time to time, make additional purchases" or reduce its position, and it may use derivatives with institutional counterparties tied to Seaport’s stock.

**Investor's Background**

General Atlantic, L.P. is a Delaware limited partnership that invests in companies for long-term growth. The firm is a global growth equity investor known for backing healthcare, technology, and life sciences businesses. It typically partners with management teams, provides strategic guidance, and supports scaling and governance.

Original SEC Filing: Seaport Therapeutics, Inc. \[ SPTX \] - SCHEDULE 13D - May. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [Wall Street Analysts Are Bullish on Top Healthcare Picks](https://longbridge.com/en/news/287451534.md)
- [12:51 ETPrezent Vivo and Nested Knowledge Partner to Bring AI-Powered Competitive Intelligence to Life Sciences Teams](https://longbridge.com/en/news/287663043.md)
- [How Congress can unleash Main Street’s growth](https://longbridge.com/en/news/287394420.md)
- [12:03 ETPRovoke Media Honors MediaSource as One of 2026's Best PR Agencies in the US](https://longbridge.com/en/news/287660023.md)
- [Tecan Establishes Direct Sales and Specialist Lab Automation Service Operations in India](https://longbridge.com/en/news/287614688.md)